Department of Chemistry and Center for Photochemical Sciences, Bowling Green State University, Bowling Green, OH 43403, USA.
Front Biosci (Elite Ed). 2024 Sep 19;16(3):28. doi: 10.31083/j.fbe1603028.
While monoclonal antibodies have shown success in cancer immunotherapy, their limitations prompt exploration of alternative approaches such as aptamers and peptides targeting programmed death ligand 1 (PD-L1). Despite the significance of these biotechnological tools, a comprehensive review encompassing both aptamers and peptides for PD-L1 targeting is lacking. Addressing this gap is crucial for consolidating recent advancements and insights in this field. Biotechnological advances leveraging aptamers and peptides represent a cutting-edge approach in refining the targeting proteins. Our review aims to provide valuable guidance for researchers and clinicians, highlighting the biotechnological advances utilizing aptamers and peptides refining PD-L1 targeting.
虽然单克隆抗体在癌症免疫疗法中已经显示出了成功，但它们的局限性促使人们探索其他方法，如针对程序性死亡配体 1（PD-L1）的适体和肽。尽管这些生物技术工具意义重大，但缺乏对适体和肽靶向 PD-L1 的全面综述。解决这一差距对于巩固该领域的最新进展和见解至关重要。利用适体和肽的生物技术进展代表了一种用于精确定位蛋白质的前沿方法。我们的综述旨在为研究人员和临床医生提供有价值的指导，强调利用适体和肽精确定位 PD-L1 的生物技术进展。
